ARK Invest bought 1.25M shares of Recursion Pharmaceuticals for $4.33M ARK added 37,075 CRISPR Therapeutics shares worth $1.97M PagerDuty was the biggest sell at $3.89M for 566,650 shares ARK also cut ...

Abstract: This paper studies the control-oriented recursive identification of finite impulse response systems with binary-valued observations. Inspired by the Maximum Likelihood method, a novel ...

From electronic health records and blood tests to the stream of data from wearable devices, the amount of health information people generate is accelerating rapidly. Yet, many users struggle to ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...

aRobert N. Butler Columbia Aging Center, Columbia University, New York, NY, USA bDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA cCarolina ...

Today, a brief rundown of news involving Insmed and Recursion Pharmaceuticals, as well as updates from Odyssey Therapeutics, Gilead Sciences and Novo Nordisk that you may have missed. AbbVie reached ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Viktor Peterson, part of the CISA task force ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Dany Lepage discusses the architectural ...